Abiopharma

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

LyondellBasell to address 2025 Goldman Sachs Industrials and Materials Conference

Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes

embecta Announces Quarterly Cash Dividend

OUE Healthcare Limited - Announcement

Disclosures Pursuant To Rules 704(33) And 728 Of The Catalist Rules

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS